Abstract
Apigenin has gained interest recently among researchers as a potential chemotherapeutic agent in cancer, including colorectal cancer, due to its established antiproliferative activity in vitro. Despite its impressive anticancer activity in vitro, poor water solubility and nonspecific distribution in vivo make it difficult for its emergence as a drug candidate. To overcome the problems, we formulated aptamer-conjugated apigenin-loaded nanoparticle (apt-ANP) to target against Epithelial Cell Adhesion Molecule (EpCAM), overexpressed as a surface biomarker of colorectal cancer cells. Aptamer-conjugation was conducted on the prepared nanoparticle, characterized (by SEM, TEM and AFM) and evaluated for its antiproliferative activity towards in vitro colon carcinoma cells and in vivo colorectal cancer model. The aptamer-conjugated nanoformulation had an average size about 226 nm, smooth surface, 17.5±1.3% drug loading and a sustained drug release profile. Pharmacokinetic and biodistribution data demonstrated an enhanced retention time of apt-ANP in colon as compared to free-drug and aptamer-free apigenin-loaded nanoparticle (ANP). Apt-ANP enhanced therapeutic efficacy to colorectal cancer cells whereas minimized off-target cytotoxicity to normal cells.
Funding Information
  • Department of Biotechnology , Ministry of Science and Technology

This publication has 52 references indexed in Scilit: